Tango Therapeutics, Inc. ((TNGX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tango Therapeutics, Inc. is conducting a clinical study titled A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors. The study aims to determine the recommended dose for Phase 2, assess the safety and tolerability of the combination therapy, and evaluate the pharmacokinetics and initial antineoplastic activity of TNG260 in patients with STK11-mutated solid tumors.
The interventions being tested are TNG260, a CoREST inhibitor administered orally, and pembrolizumab, an anti-PD-1 antibody administered intravenously. These drugs are intended to treat advanced solid tumors with STK11 mutations.
The study is interventional, non-randomized, and follows a sequential intervention model with no masking. It is designed to escalate doses in Phase 1 and expand doses in Phase 2, primarily focusing on treatment.
The study began on April 18, 2023, with an estimated primary completion date in 2025 and the last update submitted on July 22, 2025. These dates are crucial for tracking the study’s progress and potential market impact.
This update may influence Tango Therapeutics’ stock performance positively, as successful trials could enhance investor confidence and market positioning, especially in the competitive oncology sector. Investors should monitor developments closely as they could affect industry dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.